Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice.
Animals
Calcium
/ metabolism
Cannabidiol
/ isolation & purification
Cannabinoids
/ isolation & purification
Cannabis
/ chemistry
Cell Differentiation
/ drug effects
Cell Line
Dose-Response Relationship, Drug
Dronabinol
/ analogs & derivatives
Dystrophin
/ genetics
Endocannabinoids
/ metabolism
Humans
Male
Mice
Muscle Strength
/ drug effects
Muscle, Skeletal
/ drug effects
Muscular Dystrophy, Duchenne
/ drug therapy
Myoblasts
/ drug effects
Transient Receptor Potential Channels
/ metabolism
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
08
04
2018
revised:
08
07
2018
accepted:
12
07
2018
pubmed:
4
8
2018
medline:
22
7
2020
entrez:
4
8
2018
Statut:
ppublish
Résumé
Duchenne muscular dystrophy (DMD), caused by dystrophin deficiency, results in chronic inflammation and irreversible skeletal muscle degeneration. Moreover, the associated impairment of autophagy greatly contributes to the aggravation of muscle damage. We explored the possibility of using non-euphoric compounds present in Cannabis sativa, cannabidiol (CBD), cannabidivarin (CBDV) and tetrahydrocannabidivarin (THCV), to reduce inflammation, restore functional autophagy and positively enhance muscle function in vivo. Using quantitative PCR, western blots and [Ca CBD and CBDV promoted the differentiation of murine C2C12 myoblast cells into myotubes by increasing [Ca We provide new insights into plant cannabinoid interactions with TRP channels in skeletal muscle, highlighting a potential opportunity for novel co-adjuvant therapies to prevent muscle degeneration in DMD patients. This article is part of a themed section on 8
Sections du résumé
BACKGROUND AND PURPOSE
Duchenne muscular dystrophy (DMD), caused by dystrophin deficiency, results in chronic inflammation and irreversible skeletal muscle degeneration. Moreover, the associated impairment of autophagy greatly contributes to the aggravation of muscle damage. We explored the possibility of using non-euphoric compounds present in Cannabis sativa, cannabidiol (CBD), cannabidivarin (CBDV) and tetrahydrocannabidivarin (THCV), to reduce inflammation, restore functional autophagy and positively enhance muscle function in vivo.
EXPERIMENTAL APPROACH
Using quantitative PCR, western blots and [Ca
KEY RESULTS
CBD and CBDV promoted the differentiation of murine C2C12 myoblast cells into myotubes by increasing [Ca
CONCLUSION AND IMPLICATIONS
We provide new insights into plant cannabinoid interactions with TRP channels in skeletal muscle, highlighting a potential opportunity for novel co-adjuvant therapies to prevent muscle degeneration in DMD patients.
LINKED ARTICLES
This article is part of a themed section on 8
Identifiants
pubmed: 30074247
doi: 10.1111/bph.14460
pmc: PMC6487563
doi:
Substances chimiques
Cannabinoids
0
Dystrophin
0
Endocannabinoids
0
Transient Receptor Potential Channels
0
Cannabidiol
19GBJ60SN5
tetrahydrocannabivarin 9
28172-17-0
Dronabinol
7J8897W37S
cannabidivarin
I198VBV98I
Calcium
SY7Q814VUP
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1568-1584Informations de copyright
© 2018 The British Pharmacological Society.
Références
Cell Calcium. 1997 Aug;22(2):75-82
pubmed: 9292225
J Cell Sci. 2013 Dec 1;126(Pt 23):5325-33
pubmed: 24293330
Neurobiol Aging. 2010 Jul;31(7):1205-14
pubmed: 18823681
J Vis Exp. 2013 Jun 02;(76):
pubmed: 23770643
Cannabis Cannabinoid Res. 2017 Mar 01;2(1):34-47
pubmed: 28861503
Int J Exp Pathol. 2003 Aug;84(4):165-72
pubmed: 14632630
Methods Mol Biol. 2013;937:37-47
pubmed: 23007578
Neuromuscul Disord. 1993 Sep-Nov;3(5-6):533-5
pubmed: 8186706
Diabetes Care. 2016 Oct;39(10):1777-86
pubmed: 27573936
Br J Pharmacol. 2017 Dec;174 Suppl 1:S225-S271
pubmed: 29055036
Br J Pharmacol. 2015 Jul;172(13):3189-93
pubmed: 25964986
JAMA. 2017 Jul 25;318(4):323
pubmed: 28742905
Front Pharmacol. 2016 Nov 08;7:422
pubmed: 27877130
Pharmacol Res. 2011 Apr;63(4):294-9
pubmed: 21215315
Curr Med Chem. 2010;17(14):1430-49
pubmed: 20166923
Br J Pharmacol. 2011 Aug;163(7):1479-94
pubmed: 21175579
Free Radic Biol Med. 2014 Mar;68:260-7
pubmed: 24398069
Cannabis Cannabinoid Res. 2017 Jun 01;2(1):139-154
pubmed: 28861514
Br J Pharmacol. 2019 May;176(10):1568-1584
pubmed: 30074247
Neurotherapeutics. 2015 Oct;12(4):692-8
pubmed: 26271952
Dis Model Mech. 2015 Mar;8(3):195-213
pubmed: 25740330
J Hum Genet. 2017 Oct;62(10):871-876
pubmed: 28566768
Prog Lipid Res. 2016 Apr;62:107-28
pubmed: 26965148
Br J Clin Pharmacol. 2013 Feb;75(2):323-33
pubmed: 22625422
Cardiovasc Toxicol. 2012 Mar;12(1):1-9
pubmed: 21938493
J Pathol. 2007 Jan;211(2):134-43
pubmed: 17200947
Cardiovasc Res. 2013 Sep 1;99(4):760-8
pubmed: 23786999
J Neurol. 2011 Sep;258(9):1610-23
pubmed: 21399986
Br J Pharmacol. 2018 Apr;175(7):987-993
pubmed: 29520785
J Biol Chem. 2005 Apr 8;280(14):13424-32
pubmed: 15691846
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106
pubmed: 29149325
Br J Pharmacol. 2017 Dec;174 Suppl 1:S160-S194
pubmed: 29055033
J Cell Biol. 2001 May 14;153(4):F9-12
pubmed: 11352947
Prog Chem Org Nat Prod. 2017;103:103-131
pubmed: 28120232
Sci Rep. 2016 Feb 23;6:22007
pubmed: 26902776
Cell Death Differ. 2016 Nov 1;23(11):1839-1849
pubmed: 27447110
CNS Neurosci Ther. 2014 Dec;20(12):1021-8
pubmed: 25417929
Prostaglandins Other Lipid Mediat. 2016 Jan;122:54-63
pubmed: 26732541
Br J Pharmacol. 2014 May;171(9):2426-39
pubmed: 24641282
Br J Pharmacol. 2017 Dec;174 Suppl 1:S272-S359
pubmed: 29055034
Drug Des Devel Ther. 2016 Aug 30;10:2745-58
pubmed: 27621596
J Biochem Biophys Methods. 2004 Mar 31;58(3):227-37
pubmed: 15026209
Br J Pharmacol. 2010 Aug;160(7):1577-9
pubmed: 20649561
J Vis Exp. 2012 Feb 13;(60):
pubmed: 22349010
J Vis Exp. 2014 Mar 27;(85):
pubmed: 24747372
Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):E2472-81
pubmed: 24927567
Br J Pharmacol. 2012 Jul;166(5):1738-43
pubmed: 22300342
Biomed Res Int. 2015;2015:891972
pubmed: 26380303
Front Aging Neurosci. 2014 Jul 24;6:188
pubmed: 25104934
Trends Mol Med. 2016 Jun;22(6):479-496
pubmed: 27161598
Curr Opin Pharmacol. 2012 Jun;12(3):326-34
pubmed: 22349418
Skelet Muscle. 2015 May 01;5:16
pubmed: 25987977
ACS Chem Neurosci. 2014 Nov 19;5(11):1131-41
pubmed: 25029033
Br J Pharmacol. 2012 Dec;167(8):1629-42
pubmed: 22970845
Br J Pharmacol. 2015 Feb;172(3):737-53
pubmed: 25257544
Physiol Res. 2008;57 Suppl 3:S59-68
pubmed: 18481914
J Cell Physiol. 2016 Oct;231(10):2275-85
pubmed: 26892397
Cell Mol Life Sci. 2013 Dec;70(23):4585-602
pubmed: 23775131
FASEB J. 2016 Nov;30(11):3682-3689
pubmed: 27435265
Nat Med. 2013 Jan;19(1):101-6
pubmed: 23202294
Br J Pharmacol. 2017 Dec;174 Suppl 1:S17-S129
pubmed: 29055040
Nat Med. 2015 Dec;21(12):1455-63
pubmed: 26569381
AAPS J. 2009 Mar;11(1):109-19
pubmed: 19199042
Eur J Biochem. 2004 May;271(10):1814-9
pubmed: 15128291
J Pharmacol Exp Ther. 2002 Dec;303(3):1052-60
pubmed: 12438527
Cardiovasc Res. 2015 Apr 1;106(1):153-62
pubmed: 25616416
J Pharmacol Exp Ther. 2010 Mar;332(3):811-20
pubmed: 20040580